Form 4: Cigna Officer Evanko Reports Equity Transactions

Cigna Group officer Brian C. Evanko reported the acquisition of common stock and stock options, alongside disposals for tax obligations, reflecting performance-based awards and restricted share vesting.

Summary

• Brian C. Evanko, an officer of Cigna Group, acquired 6,428 shares of common stock on February 27, 2026, as a settlement for strategic performance shares from the 2023-2025 performance period.
• Evanko also acquired 9,787 restricted shares of common stock on February 27, 2026, which will vest in three equal annual installments starting March 1, 2027.
• Concurrently, 2,979 shares were disposed of at $287.55 to cover tax obligations related to the settlement of strategic performance shares.
• An additional 1,788 shares were disposed of at $287.55 to satisfy tax obligations upon the vesting of restricted shares.
• Evanko acquired 15,082 employee stock options with an exercise price of $287.5475 on February 27, 2026, which will vest in three equal annual installments beginning March 1, 2027, and expire on February 27, 2036.
• Following these transactions, Evanko directly holds 37,917 shares of common stock and 15,082 employee stock options.
• Indirect holdings include 25,614 shares via a grantor retained annuity trust (transferred December 11, 2025) and 909.1576 shares in The Cigna Group's 401(k) Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation and tax-related transactions, which are generally neutral but reflect the achievement of performance goals and ongoing incentive alignment.

Positives

• Acquisition of 6,428 shares of common stock due to the settlement of strategic performance shares, indicating achievement of company performance goals for the 2023-2025 period.
• Grant of 9,787 restricted shares and 15,082 employee stock options, representing future equity incentives for the officer.

Negatives

• Disposal of 2,979 shares and 1,788 shares (totaling 4,767 shares) at $287.55 per share to cover tax obligations, which reduces direct beneficial ownership.

Future Outlook

The filing indicates future vesting events for restricted shares and employee stock options, with installments beginning March 1, 2027, and options expiring on February 27, 2036, suggesting long-term incentive alignment.

Industry Context

StockSavvy.ai notes that these transactions are routine insider filings reflecting executive compensation structures common in the healthcare and insurance industry, where performance-based equity awards and long-term incentives are standard practice to align management interests with shareholder value over multi-year periods.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of performance share settlements, restricted share grants, and stock option awards aligns with typical executive compensation packages seen in large-cap healthcare companies such as UnitedHealth Group (UNH), Elevance Health (ELV), and Humana (HUM).
• These companies frequently utilize a mix of time-based and performance-based equity to incentivize executives, with vesting schedules often spanning three to five years.
• The disposal of shares for tax obligations is also a standard practice for executives receiving equity compensation.

Related Party Transactions

• The transactions involve an officer of Cigna Group acquiring and disposing of company securities, which are inherently related-party dealings as part of executive compensation and personal investment strategies.

Stakeholder Impact

• Shareholders: The transactions reflect the company's executive compensation strategy, aligning management incentives with shareholder interests through performance-based awards and long-term equity. The disposal of shares for tax purposes is a common occurrence and does not indicate a change in company fundamentals.
• Employees: The filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• Vesting of 9,787 restricted shares in three equal annual installments beginning March 1, 2027.
• Vesting of 15,082 employee stock options in three equal annual installments beginning March 1, 2027.
• Potential exercise of employee stock options before their expiration on February 27, 2036.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, including the settlement of performance shares, grants of restricted stock and options, and tax-related share disposals. These transactions are standard for a company of Cigna's size and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company performance and market outlook rather than these specific insider transactions.

Keywords

Cigna Group, CI, Brian C. Evanko, Form 4, Insider Trading, Stock Options, Restricted Stock, Performance Shares, Equity Compensation, Beneficial Ownership, SEC Filing